Screening for Diabetes: Can We Afford Not to Screen?

Annals of Internal Medicine

Volumn 140, Issue 9, 2004, Pages

  Nathan, David M ^a   Herman, William H ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE THERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; EYE DISEASE; GLUCOSE BLOOD LEVEL; HEALTH CARE DELIVERY; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCREENING TEST; TREATMENT INDICATION; COST BENEFIT ANALYSIS; DIABETIC ANGIOPATHY; ECONOMICS; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; MASS SCREENING;

EID: 2342617528     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-140-9-200405040-00017     Document Type: Review

References (20)

1. Wild S, Roglic G, Sicree R, Green A, King H. Global burden of diabetes mellitus in the year 2000. Global Burden of Disease. Geneva: World Health Organization; 2003.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7. [PMID: 11742409]
3. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:676-85. [PMID: 8487827].
4. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15:815-9. [PMID: 1516497]
5. Diabetes Control and Complications Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications trial. N Engl J Med. 1993;329:977-86. [PMID: 8366922]
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. [PMID: 9742976]
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-13. [PMID: 9732337]
8. Davis TM, Stratton IM, Fox CJ, Holman RR, Turner RC. U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care. 1997;20:1435-41. [PMID: 9283793]
9. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123-31. [PMID: 3556287]
10. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the dock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-8. [PMID: 2338751]
11. Standards of medical care in diabetes. Diabetes Care. 2004;27 Suppl 1:S15-35. [PMID: 14693923]
12. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
13. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004;140:689-99.
14. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. JAMA. 1998;280:1757-63. [PMID: 9842951]
15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947]
16. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, et al. Valuing health-related quality of life in diabetes. Diabetes Care. 2002;25:2238-43. [PMID: 12453967]
17. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ. 1998;317:371-5. [PMID: 9694750]
18. Herman WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26:36-47. [PMID: 12502656]
19. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-16. [PMID: 12814710]
20. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-74. [PMID: 11955024]